Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long‐term experience

There is limited evidence about the real‐world survival of apremilast in patients with psoriasis, especially over the long term. To evaluate the long‐term survival of apremilast and its predictive factors when used to treat psoriasis. A retrospective hospital‐based study, including data collected fr...

Full description

Saved in:
Bibliographic Details
Published in:Dermatologic therapy 2022-07, Vol.35 (7), p.e15583-n/a
Main Authors: Galache‐Osuna, Cristina, Reyes‐García, Sebastián, Salgueiro, Esther, Bordallo‐Landa, Javier, Lozano, Ana, Vázquez‐López, Francisco, Santos‐Juanes, Jorge
Format: Article
Language:English
Subjects:
apremilast
drug survival
PASI
psoriasis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is limited evidence about the real‐world survival of apremilast in patients with psoriasis, especially over the long term. To evaluate the long‐term survival of apremilast and its predictive factors when used to treat psoriasis. A retrospective hospital‐based study, including data collected from 104 patients. Survival curves were estimated using the Kaplan–Meier estimator. Proportional hazard Cox regression models were used for multivariate analysis. The average duration of the treatment before discontinuation was 28.82 months (95% CI, 22.08–35.57 months) and the median was 12 months (95% CI, 2.68–21.31 months). The retention rates were 51% (1 year), and 33% (5 years). The survival study revealed statistically significant differences between patients with PASI
ISSN:1396-0296
1529-8019
DOI:10.1111/dth.15583